Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Published:2011-10-28 Issue:5 Volume:26 Page:893-901
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pollyea D A,Kohrt H E,Gallegos L,Figueroa M E,Abdel-Wahab O,Zhang B,Bhattacharya S,Zehnder J,Liedtke M,Gotlib J R,Coutre S,Berube C,Melnick A,Levine R,Mitchell B S,Medeiros B C

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011294.pdf

Reference37 articles.

1. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187.

2. Dombret H, Raffoux E, Gardin C . Acute myeloid leukemia in the elderly. Semin Oncol 2008; 35: 430–438.

3. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.

4. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ . Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982; 60: 309–315.

5. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DCAF15 control of cohesin dynamics sustains acute myeloid leukemia;Nature Communications;2024-07-03

2. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI‐1 trial;British Journal of Haematology;2023-11-28

3. Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes;Cancer Management and Research;2022-12

4. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms;Frontiers in Immunology;2022-10-12

5. Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective;Cancers;2022-06-25